

References

1. Cada DJ. Carbamazepine. Drug Facts and Comparisons. Facts and Comparisons 1997; 1766-1771.
2. USP DI: Drug Information for The Health Care Profesional. Rockville,MD: The United States Pharmacopeial Convention, 1992: 806-813.
3. Mcevdly GK. Carbamazepine. AHFS. American Society of Health-System Pharmacists 1995; 1449-1453.
4. Liu H, Delgado MR. Therapeutic drug concentration monitoring using saliva samples. Clin Pharmacokinet 1999; 36(6): 453-470.
5. Schramm W, Annesley TM, Siegel GJ, Sackellares, Smith RH. Measurement of phenytoin and carbamazepine in an ultrafiltrate of saliva. Ther Drug Monit 1991; 13: 452-460.
6. Gorodischer R, Burtin P, Verjee Z, Hwang P, Gideon G. Is saliva suitable for therapeutic monitoring of anticonvulsants in children : an evaluation in the routine clinical setting. Ther Drug Monit 1997; 19: 637-642.
7. Westenberg HGM, Kleijn E, Oei TT, Zeeuw RA. Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva. Clin Pharmacol Ther 1978; 23(3): 320-327.
8. Rylance GW, Butcher GM, Moreland T. Saliva carbamazepine levels in children. BMJ 1977: 1481.

9. Miles MV, Tennison MB, Greenwood RS. Intraindividual variability of carbamazepine, phenobarbital, and phenytoin concentrations in saliva. *Ther Drug Monit* 1991; 13: 166-171.
10. Chambers RE, Homeida M, Hunter KR, Teague RH. Salivary carbamazepine concentrations. *Lancet* 1977: 656-657.
11. Gilman AG, Goodman LS (Eds). *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, 8th ed. New York: McMillan 1990; 447-449.
12. Rane A, Hojer B, Wilson JT. Kinetics of carbamazepine and its 10,11-epoxide metabolite in children. *Clin Pharmacol Ther* 1980; 19(3): 276-283.
13. Fromm GH, Chattha AS, Terrence CF, Glass JD. Do phenytoin and carbamazepine depress excitation and/or facilitate inhibition ?. *Eur J Pharmacol* 1982; 78: 403-409.
14. Fromm GH. Effects of different classes of antiepileptic drugs on brain-stem pathways. *Fed Proc* 1985; 44: 2432-2435.
15. Macdonald RL, McLean MJ, Skeritt JH. Anticonvulsant drug mechanisms of action. *Fed Proc* 1985; 44: 2634-2639.
16. Olpe HR, Baudry M, Jones RSG. Electrophysiological and neurological investigations on the action of carbamazepine on the rat hippocampus. *Eur J Pharmacol* 1985; 110: 71-80.
17. Schauf CL, David FA, Maeder J. Effects of carbamazepine on the ionic conductances of *Myxicola* giant axons. *J Pharmacol Exp Ther* 1974; 189: 538-543.

18. Willow M, Catterall WA. Inhibition of binding of [³H]batrachotoxin A 20 α -benzoate to sodium channels by anticonvulsant drugs diphenylhydantoin and carbamazepine. *Mol Pharmacol* 1982; 22: 627-635.
19. Willow M, Kuenzel EA, Catterall WA. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. *Mol Pharmacol* 1984; 25: 228-235.
20. Willow M, Gono T, Catterall WA. Voltage clamp analysis of the inhibitory action of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells. *Mol Pharmacol* 1985; 27: 549-558.
21. Purdy RE, Julien RM, Fairhurst AS, Terry MD. Effect of carbamazepine on the in vitro uptake and release of norepinephrine in adrenergic nerves of rabbit aorta and the whole brain synaptosomes. *Epilepsia* 1977; 18: 251-257.
22. Waldmeier PC, Baumann PA, Fehr B, De Herdt P, Maitre L. Carbamazepine decrease catecholamine in the rat. *J Pharmacol Exp Ther* 1984; 231: 166-172.
23. Consolo S, Bianchi S, Ladinsky H. Effect of carbamazepine on cholinergic parameters in rat brain areas. *Neuropharmacol* 1976; 15: 653-657.
24. Weiss SRB, Post RM, Patel J, Marangos PJ. Differential mediation of the anticonvulsant effect of carbamazepine and diazepam. *Life Sci* 1985; 36: 2413-2419.
25. Richards JG, Mohler H, Haefely W. Benzodiazepine binding sites: receptors or acceptor?. *Trends Pharmacol Sci* 1982; 3: 233-235.
26. Pellow S, File SE. Behavioural action of Ro 5-4864: a peripheral-type benzodiazepine?. *Life Sci* 1984; 35 : 229-240.

27. Moselli PL, Gerna M, Garattini S. Carbamazepine plasma and tissue levels in the rat. *Biochem Pharmacol* 1971; 20: 2043-2047.
28. Dragonow M, Goddard GV, Laverty R. Is adenosine an endogenous anticonvulsant ?. *Epilepsia* 1985; 26: 480-487.
29. Dunwiddie TV, Worth T. Sedative and anticonvulsant effects of adenosine analogs in mouse and rat. *J Pharmacol Exp Ther* 1982; 220: 70-76.
30. Ault B, Wang CM. Adenosine inhibits epileptiform activity arising in hippocampus area CA3. *Br J Pharmacol* 1986; 87: 659-703.
31. Hollin C, Stone TW. Adenosine inhibition of amino butyric acid release from slices of rat cerebral cortex. *Br J Pharmacol* 1980; 69: 107-112.
32. Corradetti R, Conte GL, Moroni F, Passani MB, Pepeu G. Adenosine decrease aspartate and glutamate release from rat hippocampus slices. *Eur J Pharmacol* 1984; 104: 19-26.
33. Skerritt JH, Johnston GAR, Chow SC. Interactions of the anticonvulsant carbamazepine with adenosine receptors: 2. pharmacological studies. *Epilepsia* 1983; 24: 643-650.
34. Skerritt JH, Davies LP, Johnston GAR. A purinergic component in the anticonvulsant action of carbamazepine ?. *Eur J Pharmacol* 1982; 82: 195-197.
35. Marangos PJ, Post RM, Partel J, Zander K, Parma A, Weiss S. Specific and potent interactions of carbamazepine with brain adenosine. *Eur J Pharmacol* 1983; 93: 175-182.
36. Skerritt JH, Davies LP, Johnston GAR. Interactions of anticonvulsant carbamazepine with adenosine receptors : 1. Neurochemical studies. *Epilepsia* 1983; 24: 634-642.

37. Marangos PJ, Weiss SRB, Montgomery P, et al. Chronic carbamazepine treatment increase brain adenosine receptors. *Epilepsia* 1985; 26: 493-498.
38. Phillis JW. Interactions of the anticonvulsant diphenylhydantoin and carbamazepine with adenosine on cerebral cortical neurons. *Epilepsia* 1984; 25: 765-772.
39. Weir RL, Anderson SM, Daly JW. Inhibition of N⁶-[³H]cyclohexyladenosine binding by carbamazepine. *Epilepsia* 1990; 31: 503-512.
40. Bertilsson L. Clinical pharmacokinetics of carbamazepine. *Clin Pharmacokinet* 1978; 3: 128-143.
41. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. *Clin Pharmacokinet* 1986; 11: 177-198.
42. Eichelbaum M, Kothe KW, Hoffmann F. Kinetics and metabolism of carbamazepine during combined antiepileptic drug therapy. *Clin Pharmacol Ther* 1979; 26(3): 366-371.
43. Berre J, Didey F, Delion F, Tillement J. Problems in therapeutic drug monitoring: free drug level monitoring. *Ther Drug Monit* 1988; 10(2): 133-143.
44. Kankirawatana P. Salivary antiepileptic drug levels in Thai children. *J Med Assoc Thai* 1999; 82(1): 80-88.
45. Svensson CK, Woodruff MN, Buxter JG, Lalka D. Free drug concentration monitoring in clinical practice rationale and current status. *Clinical Pharmacokinet* 1986; 11: 450-469.
46. Hoopeer WD, Dubetz DK, Bochner F, et al. Plasma protein binding of carbamazepine. *Clin Pharmacol Ther* 1975; 17(4): 433-440.

47. Liu H, Delgado MR. Improved therapeutic monitoring of drug interactions in epileptic children using carbamazepine polytherapy. *Ther Drug Monit* 1994; 16: 132-138.
48. Liu H, Delgado M, Iannaccone ST, Forman LJ, Eggers CM. Determination of total and free carbamazepine and the principal metabolites in serum by high-performance liquid chromatography with photodiode-array detection. *Ther Drug Monit* 1993; 15(4): 317-327.
49. Liu H, Delgado MR. Influence of sex, age, weight, and carbamazepine dose on serum concentrations, concentration ratios, and level/dose ratios of carbamazepine and its metabolites. *Ther Drug Monit* 1994; 16(5): 469-476.
50. Tomson T, Svensson JO, Brown PH. Relationship of intraindividual dose to plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism. *Ther Drug Monit* 1989; 11: 533-539.
51. Eichelbaum M, Tomson T, Tybring G, Bertilsson L. Carbamazepine metabolism in man: induction and pharmacogenetic aspects. *Clin pharmacokinet* 1985; 10: 80-90.
52. Thomson AH, Brodie MJ. Pharmacokinetic optimisation of anticonvulsant therapy. *Clin Pharmacokinet* 1992; 23(3): 216-230.
53. Bertilsson L, Tomson T, Tybring G. Pharmacokinetic: Time-dependent changes-auto induction of carbamazepine epoxidation. *J Clin Pharmacol* 1986; 26: 459-462.
54. Bertilsson L, Hojer B, Tybring G, Osterloh J, Rane A. Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. *Clin Pharmacol Ther* 1980; 27(1): 83-88.

55. Liu H, Delgado M. Interactions of phenobarbital and phenytoin with carbamazepine and its metabolites' concentrations, concentration ratios, and level/dose ratios in epileptic children. *Epilepsia* 1995; 36: 249-254.
56. Perucca E. Pharmacokinetic interactions with antiepileptic drugs. *Clin Pharmacokinet* 1982; 7: 57-84.
57. Wagner ML, Rimmel RP, Graves NM, Leppik IE. Effect of felbamate on carbamazepine and its major metabolites. *Clin Pharmacol Ther* 1993; 53(5): 536-543.
58. Rimmel RP, Miller SA, Graves NM. Simultaneous assay of felbamate plus carbamazepine, phenytoin, and their metabolites by liquid chromatography with mobile phase optimization. *Ther Drug Monit* 1990; 12: 90-96.
59. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. *Clin Pharmacokinet* 1996; 31(3): 198-214.
60. Neef C, Straaten IV. An interaction between cytostatic and anticonvulsant drugs. *Clin Pharmacol Ther* 1988; 43(4): 372-375.
61. Pearson HJ. Interaction of fluoxetine with carbamazepine. *J Clin Psychiatry* 1990; 51(3): 126.
62. Grimsley SR, Jann MW, Carter JG, D'Mello AP, D'Souza MJ. Increased carbamazepine plasma concentrations after fluoxetine coadministration. *Clin Pharmacol Ther* 1991; 50(1): 10-15.
63. Toppet NT, Duret ME, Coers C. Cimetidine interaction with carbamazepine. *Ann Intern Med* 1981; 94(4): 544.

64. McBride MC, Rochester. Serum carbamazepine levels are increased by acetazolamide. *Ann Neurol* 1984; 16: 393.
65. Macphee GA, McInnes GT, Thompson GG, Brodie MJ. Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. *Lancet* 1986: 700-703.
66. Bahls FH, Ozuna J, Ritchie DE. Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin. *Neurology* 1991; 41: 740-742.
67. Wong YY, Ludden TM, Bell RD. Effect of erythromycin on carbamazepine kinetics. *Clin Pharmacol Ther* 1983; 33(4): 460-464.
68. Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. *Clin Pharmacokinet* 1995; 29(3): 172-191.
69. Browne TR, Szabo GK, Evans JE, Evans BA, Greenblatt DJ, Mikati MA. Carbamazepine increase phenytoin serum concentration and reduces phenytoin clearance. *Neurology* 1988; 38: 1146-1150.
70. Lia AA, Levy RH, Cutler RE. Time-course of interaction between carbamazepine and clonazepam in normal man. *Clin Pharmacol Ther* 1978; 24(3): 316-323.
71. Hansen JM, Siersbaek-Nielsen K, Skovsted L. Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. *Clin Pharmacol Ther* 1971; 12(3): 539-543.
72. Kendall AG, Boivin M. Warfarin-carbamazepine interaction. *Ann Intern Med* 1981; 94(2): 280.

73. Alvarez JS, Sacristan Del Castillo JA, Alsar Ortiz MJ. Effect of carbamazepine on ciclosporin blood level. *Nephron* 1991; 58: 235-236.
74. Park BK, Breckenridge AM. Clinical implications of enzyme induction and enzyme inhibition. *Clin Pharmacokinet* 1981; 6: 1-24.
75. Choonara IA, Rane A. Therapeutic drug monitoring of anticonvulsants. *Clin Pharmacokinet* 1990 ; 18(4): 318-328.
76. Levy RH, Pitlick WH, Troupin AS, Green JR, Neal JM. Pharmacokinetics of carbamazepine in normal man. *Clin Pharmacol Ther* 1985; 17(6): 657-668.
77. Snead OC, Hosey LC. Exacerbation of seizures in children by carbamazepine. *Eng J Med* 1983; 313: 916-921.
78. Hamilton MJ, Cohen AF, Yuen AWC, Et al. Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. *Epilepsia* 1993; 34(1): 166-173.
79. Pugh CB, Garnett WR. Current issue in the treatment of epilepsy. *Clin Phar* 1991; 10: 335-358.
80. Eadie MJ. The role of therapeutic drug monitoring in improving the cost effectiveness of anticonvulsant therapy. *Clin Pharmacokinet* 1995; 29(1): 29-35.
81. Horning MG, Brown L, Nowlin J, Lertratanangkoon K, Kellaway P, Zion TE. Use of saliva in therapeutic drug monitoring. *Clin Chem* 1977; 23(2): 157-164.

82. Silpakit O, Amornpichetkoon M, Kaojarern S. Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients. *Ann Pharmacother* 1997; 31: 548-552.
83. Mucklow JC, Bending MR, Kahn GC, Dollery CT. Drug concentration in saliva. *Clin Pharmacol Ther* 1978; 24(5): 563-570.
84. McAuliffe JJ, Sherwin AL, Leppik IE, Fayle SA, Pippenger CE. Salivary levels of anti-convulsants: a practical approach to drug monitoring. *Neurology* 1977: 409-413.
85. Allen UD, MBBS, MSc, et al. Percutaneous injuries among health care workers the real value of human immunodeficiency virus testing of 'Donor' blood. *Arch Intern Med* 1991; 151: 2233-2240.
86. Gorodischer R, Burtin P, Hwang P, Levine M, Koren G. Saliva versus blood sampling for therapeutic drug monitoring in children : patient and parental preferences and an economic analysis. *Ther Drug Monit* 1994; 16(5): 437-443.
87. Liu H, Delgado M, Forman LJ, Eggers CM, Montoya JL. Simultaneous determination of carbamazepine, phenytoin, phenobarbital, primidone and their principal metabolites by high-performance liquid chromatography with photodiode-array detection. *J Chromatogr* 1993; 616: 105-115.
88. Herkes GK, Mckinnon GE, Eadie MJ. Simultaneous quantitation of salivary carbamazepine, Carbamazepine-10,11-epoxide, phenytoin and phenobarbitone by high-performance liquid chromatography. *J Chromatogr* 1989: 147-154.
89. Drobitch RK, Svensson CK. Therapeutic drug monitoring in saliva. *Clin Pharmacokinet* 1992; 23(5): 365-379.

90. Rylance GW, Moreland TA. Saliva carbamazepine and phenytoin level monitoring. *Archives of disease in childhood*. 1981; 56: 637-652.
91. Furlanut M, Montanari G, Bonin P, Casara GL. Carbamazepine and carbamazepine-10,11-epoxide serum concentrations in epileptic children. *J Ped* 1985; 106(3): 491-495.
92. Paxton JW, Donald RA. Concentrations and kinetics of carbamazepine in whole saliva, parotid saliva, serum ultrafiltrate, and serum. *Clin Pharmacol Ther* 1980; 28(5): 695-702.
93. Miles MV, Tennison MB, Greenwood RS, Benoit SE, Thorn MD, Messenheimer JA, Ehle A. Evaluation of the ames seralyzer for the determination of carbamazepine, phenobarbital, and phenytoin concentrations in saliva. *Ther Drug Monit* 1990; 12(5): 501-510.
94. Rosenthal E, Hoffer E, Ben-Aryeh H, Badami S, Benderly A, Hemli Y. Use of saliva in home monitoring of carbamazepine levels. *Epilepsia* 1995; 36(1): 72-74.
95. Mihaly GM, Phillips JA, Louis WJ, Vajda FJ. Measurement of carbamazepine and its epoxide metabolite by high-performance liquid chromatography, and a comparison of assay techniques for the analysis of carbamazepine. *Clin Chem* 1977; 23(12): 2283-2287.
96. Wilson JF, Tsanaclis LM, Williams J, Tedstone JE, Richens A. Evaluation of assay techniques for the measurement of antiepileptic drugs in serum: a study based on external quality assurance measurements. *Ther Drug Monit* 1989; 11: 185-189.
97. Mackinchan JJ. Simultaneous liquid chromatographic analysis for carbamazepine and carbamazepine-10,11-epoxide in plasma and saliva by use of double internal standardization. *J Chromatogr* 1980; 181: 373-383.

98. Chelberg RD, Gunawan S, Treiman DM. Simultaneous high-performance liquid chromatographic determination of carbamazepine and its principal metabolites in human plasma and urine. *Ther Drug Monit.* 1988; 10: 188-193.
99. Kupferberg HJ. GLC Determination of carbamazepine in plasma. *J Pharm Sci* 1972; 61(2): 284-286.
100. Sawchuk RJ, Cartier LL. Simultaneous liquid-chromatographic determination of carbamazepine and its epoxide metabolite in plasma. *Clin Chem* 1982; 28(10): 2127-2130.
101. Kushida K, Ishizaki T. Concurrent determination of valproic acid with other antiepileptic drugs by high-performance liquid chromatography. *J Chromatogr* 1985; 338: 131-139.